Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncology. 2023;101(11):730-737. doi: 10.1159/000531870. Epub 2023 Aug 23.
Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients.
We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method.
The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18.
Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.
循环炎症细胞因子在肿瘤相关炎症和免疫反应中起着关键作用。最近的数据表明，几种白细胞介素（ILs）在肝细胞癌（HCC）中发挥致癌作用。然而，循环 ILs 的预测和预后价值尚待验证。我们的研究旨在评估大量 HCC 患者的血清 ILs 与总生存期（OS）和临床病理特征的相关性。
我们前瞻性地收集了 2001 年至 2014 年期间在德克萨斯大学 MD 安德森癌症中心治疗的 767 例 HCC 患者的数据和血清样本，中位随访时间为 67.4 个月（95%置信区间[CI]：52.5，83.3）。通过对数秩检验评估生物标志物与 OS 的相关性。
该队列的中位 OS 为 14.2 个月（95%CI：12，16.1 个月）。在循环 IL1-R1、IL-6、IL-8、IL-10、IL-15、IL-16 和 IL-18 水平较高的患者中，临床病理特征更为晚期，OS 显著降低。
我们的研究表明，几种血清 IL 水平是有效的预后生物标志物候选物，也是 HCC 治疗的潜在靶点。
